Loading
A phase 2 trial of Osimertinib, Amivantamab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations is a phase 2 interventional study registered as NCT05801029 by AstraZeneca, with 60 participants enrolled, started 2023-07-18 and due to reach its primary completion in 2027-10-01. Interventions recorded: Osimertinib, Amivantamab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Amivantamab, Bispecific antibodies, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/